These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 23121270)

  • 1. Pegloticase and the patient with treatment-failure gout.
    Dave AJ; Kelly VM; Krishnan E
    Expert Rev Clin Pharmacol; 2012 Sep; 5(5):501-8. PubMed ID: 23121270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alternative treatment for chronic gout could relieve pain for thousands. The recently approved intravenous drug, pegloticase, may work when other treatments don't.
    Duke Med Health News; 2013 Jan; 19(1):3. PubMed ID: 23762971
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.
    Sundy JS; Baraf HS; Yood RA; Edwards NL; Gutierrez-Urena SR; Treadwell EL; Vázquez-Mellado J; White WB; Lipsky PE; Horowitz Z; Huang W; Maroli AN; Waltrip RW; Hamburger SA; Becker MA
    JAMA; 2011 Aug; 306(7):711-20. PubMed ID: 21846852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pegloticase for treating refractory chronic gout.
    George RL; Sundy JS
    Drugs Today (Barc); 2012 Jul; 48(7):441-9. PubMed ID: 22844655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pegloticase (krystexxa) for treatment of refractory gout.
    Med Lett Drugs Ther; 2011 Feb; 53(1357):9-10. PubMed ID: 21304442
    [No Abstract]   [Full Text] [Related]  

  • 6. Pegloticase, a polyethylene glycol conjugate of uricase for the potential intravenous treatment of gout.
    Biggers K; Scheinfeld N
    Curr Opin Investig Drugs; 2008 Apr; 9(4):422-9. PubMed ID: 18393109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved health-related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: evidence from phase III randomized controlled trials.
    Strand V; Khanna D; Singh JA; Forsythe A; Edwards NL
    J Rheumatol; 2012 Jul; 39(7):1450-7. PubMed ID: 22660805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on emerging urate-lowering therapies.
    Chohan S; Becker MA
    Curr Opin Rheumatol; 2009 Mar; 21(2):143-9. PubMed ID: 19339925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pegloticase: a novel agent for treatment-refractory gout.
    Shannon JA; Cole SW
    Ann Pharmacother; 2012 Mar; 46(3):368-76. PubMed ID: 22395256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pegloticase: in treatment-refractory chronic gout.
    Lyseng-Williamson KA
    Drugs; 2011 Nov; 71(16):2179-92. PubMed ID: 22035516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase.
    Mandell BF; Yeo AE; Lipsky PE
    Arthritis Res Ther; 2018 Dec; 20(1):286. PubMed ID: 30594229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Gout: an overview of available urate lowering therapies].
    Richette P
    Ann Pharm Fr; 2012 May; 70(3):133-8. PubMed ID: 22655581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pegloticase Treatment Significantly Decreases Blood Pressure in Patients With Chronic Gout.
    Johnson RJ; Choi HK; Yeo AE; Lipsky PE
    Hypertension; 2019 Jul; 74(1):95-101. PubMed ID: 31079535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal of chronic refractory tophaceous gout with erosions with pegloticase.
    Yeter KC; Ortiz EC; Arkfeld DG
    Int J Rheum Dis; 2013 Jun; 16(3):369-70. PubMed ID: 23981765
    [No Abstract]   [Full Text] [Related]  

  • 15. Evaluation and treatment of gout as a chronic disease.
    Perez-Ruiz F; Herrero-Beites AM
    Adv Ther; 2012 Nov; 29(11):935-46. PubMed ID: 23104464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study.
    Sundy JS; Becker MA; Baraf HS; Barkhuizen A; Moreland LW; Huang W; Waltrip RW; Maroli AN; Horowitz Z;
    Arthritis Rheum; 2008 Sep; 58(9):2882-91. PubMed ID: 18759308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pegloticase failure and a possible solution: Immunosuppression to prevent intolerance and inefficacy in patients with gout.
    Berhanu AA; Krasnokutsky S; Keenan RT; Pillinger MH
    Semin Arthritis Rheum; 2017 Jun; 46(6):754-758. PubMed ID: 27769591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploratory study of radiographic change in patients with tophaceous gout treated with intensive urate-lowering therapy.
    Dalbeth N; Doyle AJ; McQueen FM; Sundy J; Baraf HS
    Arthritis Care Res (Hoboken); 2014 Jan; 66(1):82-5. PubMed ID: 23836458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetic and pharmacodynamic analysis of pegloticase in subjects with hyperuricemia and treatment-failure gout.
    Yue CS; Huang W; Alton M; Maroli AN; Waltrip RW; Wright D; Marco MD
    J Clin Pharmacol; 2008 Jun; 48(6):708-18. PubMed ID: 18420531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Case Report of Immunosuppressant Medication‒Associated Polyarticular Tophaceous Gout Successfully Treated Using the Polyethylene Glycol‒Conjugated Uricase Enzyme Pegloticase.
    Freyne B
    Transplant Proc; 2018 Dec; 50(10):4099-4101. PubMed ID: 30577324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.